Participation in 'The 113th Congress of Japan Society of Aesthetic Surgery,' May 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical') today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty Clinic, a clinic operated under the management support of SBC Medical Group, a consolidated subsidiary, presented their research findings at 'The 113th Congress of Japan Society of Aesthetic Surgery.'
Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Incorporated
The Japan Society of Aesthetic Surgery (JSAS), one of Japan's leading professional societies in the field of aesthetic medicine, brings together doctors dedicated to shaping the future of the industry. 'The 113th Congress of Japan Society of Aesthetic Surgery' was held over three days from Wednesday, May 28 to Friday, May 30, 2025, at The Okura Tokyo. Under the theme 'TO BE THE BEST -The Journey of Knowledge Never Ends-,' the congress was chaired in part by Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, who served as Vice Chair of the event. The congress provided a valuable platform for in-depth discussions on international trends and future developments in aesthetic medicine, fostering both academic and clinical insights and promoting global collaboration among experts in the field.
Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, served as Vice Chair of this Congress
At this congress, a total of 22 representatives from SBC Medical presented their research findings, including Yoshiyuki Aikawa, CEO of SBC Medical, Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group, Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group and Dr. Ayaka Nishikawa, who also served as Vice Chair of the congress. Each speaker shared insights cultivated through daily clinical practice and research in their respective fields of expertise. The event also featured lively discussions on global trends and future developments in aesthetic medicine, providing a valuable opportunity to deepen academic and clinical knowledge and to foster international collaboration.
Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group
Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group
In the rapidly evolving field of aesthetic medicine, the importance of both acquiring and sharing specialized knowledge continues to grow. As technological advancements drive increasingly diverse customer needs, it is essential not only to adopt cutting-edge technologies, but also to maintain a broad and multifaceted perspective. SBC Medical remains committed to contributing to the advancement of the aesthetic medicine industry by actively engaging with academic societies and research institutions, sharing our innovative initiatives, and incorporating the latest global knowledge and technologies into our practice.
The 113th Congress of Japan Society of Aesthetic Surgery
Venue：The Okura Tokyo
Dates：Wednesday, May 28 – Friday, May 30, 2025
Official website： https://square.umin.ac.jp/jsas113/index.html
Presentation Topics
Chair / Speaker Job Title Title
Yoshiyuki Aikawa CEO, SBC Medical Group Holdings 【Special Program/Speaker】 Practical Strategies for Cosmetic Medical Business Management and Marketing
【Special Lecture/Chair】The future of cosmetic medicine and AI
Daisuke Nakamura Chief Medical Director of Shonan Beauty Group,
Chief of Breast Augmentation at SBC 【Symposium/Speaker】Creating an attractive bust line - Fat injection breast augmentation and breast implant augmentation
Kazuhiro Igawa Representative Assistant and Technical Advisor,
Shonan Beauty Group 【Symposium/Speaker】Rhinoplasty with an awareness of harmony by considering facial parts as fonts
Ayaka Nishikawa Director of Dermatology
Department of Shonan Beauty Group 【Luncheon Seminar/Chair/Speaker】The Potential of Microneedle RF：Indications and Practical Combination Treatments in Skin Management
【Invited Lecture/Chair】Unique Treatments and Techniques with injectable Agents A 35 Year Evolution
【Symposium/Speaker】Challenges in Skin Tightening Devices: Insights from Single-Device Treatments with 6.78MHz Monopolar RF
【Sponsored Seminar/Chair】'The WHY'? -Why do we do what we do as an aesthetics injector?
【Presidential Special Program/Speaker】Evaluating the Impact of Different Approaches in Aesthetic Dermatology: A Post-Treatment Study in Identical Twins
【Sponsored Seminar/Speaker】Fine fiber sheet for application after pico-second laser treatment
Jiro Kataoka Area Medical Director and Anti-Aging Expert Doctor 【Panel Discussion/Speaker】Deep Plane Facelift for Japanese (Asians) ~My Experience and Ideas~
【Video Lecture/Chair】Fundamentals and applications of Facelift Surgery: Strategies for Addressing Age-Related Changes
Shoko Takahashi Top expert doctor in rejuvenation 【Panel Discussion/Speaker】Patient education and combination treatment to maximize patient satisfaction with thread lifting
Hiroaki Takizawa Area Doctor and Director of Jiyugaoka Clinic 【Symposium/Speaker】Revision after double eyelid surgery with sub-brow blepharoplasty
Eiko Tanaka Director of Takatsuki Hospital 【Symposium/Chair/Speaker】Innovative Approaches to Improve Labia Majora Laxity: Minimizing Scars in Reduction Surgery
Atsushi Hayashi Chief Technical Director 【Panel Discussion/Speaker】Incidence of Post-inflammatory Hyperpigmentation with Picosecond Laser in Patients with Melasma
Kanako Misono Slimming Expert Doctor 【Luncheon Seminar/Speaker】Cutting edge of Cryolipolysis: Maximize patient satisfaction with Coolsculpting
Soichiro Morikawa Anti-aging treatment expert doctor 【Luncheon Seminar/Speaker】Polynucleotide products and Hyaluronic Acid Filler
Poster Presentations
Speaker Job Title Title
Hiroshi Ohji ー Usefulness of preoperative ultrasound examination in submandibular liposuction.
Ayano Okuda Expert doctor in gynecological plastic surgery Diversifying Intimate Area Treatments ~Changes and Current Status of Pubic Hair Removal and Female Genital plastic surgery at Our Clinic~
Go Kanazawa Director of Hiroshima Clinic and Area Doctor for Hiroshima Area Lessons learned from the experience of removing limps formed by fat injection into the lower eyelid
Kaito Kuzushima Ginza Clinic Director
Top Expert Doctor in Liposuction Asian Buttocks Contouring：witout fat injection 【Evaluated with 3D Vectra】
Aiko Ssasaki Kawagoe Area Area
Doctor and Director of Kawagoe Clinic Comparison of eyelid functions before and after completely transconjunctival embedding double eyelid blepharoplasty
Yuka Takeda Director of the Esaka Institute The usefulness of next generation needle Nanosoft Microneedles
Lifting Effects and Technical Innovations in Full-Face Autologous Fat Grafting
Ryuji Tanaka Hokkaido/Tohoku Area General Manager Approach to the Management of Lower Eyelid Hollowness with Skin Laxity
Mei Nakayama ー Bilateral symmetrical enlargement within a few months after upper arm liposuction : case report
Ayaka Nishikawa Director of Dermatology
Department of Shonan Beauty Group Fine fiber sheet for application after pico-second laser treatment
Yu Hirata Director of Okayama Clinic and Area Doctor for Okayama Area Study on the direction of fat repositioning in transconjunctival blepharoplasty.
Takashi Yamamoto Director of Nagoya Institute Examination of the effects, satisfaction, and risks of orbital fat removal combined with the buried double method
Akihiro Yoshida ー Tips to improve the success rate of transconjunctival double eyelid blepharoplasty suture removal
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit https://sbc-holdings.com/
Contacts
In Asia:
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
E-mail: ir@sbc-holdings.com
In the US:
ICR LLC
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Could Buying AST SpaceMobile Stock Today Set You Up for Life?
AST SpaceMobile (NASDAQ: ASTS) is an exciting stock. It has such an interesting story backing it that some investors might wonder if buying in now could help to set them up for life. That is possible, but there's one small problem that you need to consider before stepping in here. This is what you need to know about AST SpaceMobile before you buy it. What does AST SpaceMobile do? AST SpaceMobile operates a satellite-based broadband cellular network. It is really just starting to build out that network, but it has some of the most important markets covered. That list includes the United States, Europe, and Japan. When it actually turns the network on, it should be ready to hit the ground running. One of the key features of AST SpaceMobile's business model is that it is working in partnership with some of the world's largest telecom companies. That list includes both AT&T and Verizon Communications. These providers have massive customer bases, to which they will market AST SpaceMobile's service as an add-on. The benefit is that satellite access, using a customer's existing cellphone, ensures phone service in virtually all locations. The longer-term goal for AST SpaceMobile is to provide worldwide coverage. Essentially, with no additional outlay for technology, a cellphone customer will eventually be able to ensure they have access to the internet and communications networks the world over. All it will require to take advantage of that "insurance" is a monthly fee, though there are also likely to be other options for those who only need such coverage for a short duration of time. This is a compelling story and hints that there could be a huge amount of growth ahead. That will first come from simply rolling out the service in currently covered regions. But then it will expand as AST SpaceMobile's satellite network grows over time. The problem with AST SpaceMobile So that's the glass-half-full view of things, and it is a compelling story for investors to consider. But there are always caveats to think about, and there are two big ones with AST SpaceMobile. First, launching satellites into space is not a cheap or easy thing to do. Execution will be very important. However, AST SpaceMobile only directly controls just so much of its business on this front. Even if it can build new satellites at a rapid clip, it has to get them launched into space by a third party. It's possible for spaceships to blow up, destroying their contents. A big disaster on that front would be a costly setback for AST SpaceMobile, even though it had little control over the outcome of the launch event. And that assumes that AST SpaceMobile executes very well on what it can control, which isn't a given. Second, and perhaps more worrying, is the fact that Wall Street is clearly aware of the opportunity AST SpaceMobile presents. The stock is up more than 400% over the past year, and by nearly 600% over the past three years. Even as the stock has risen in meteoric fashion, the company still has yet to turn a profit. ASTS data by YCharts. It looks like Wall Street may already be pricing in a lot of good news here. In fact, the recent stock price advance has been so swift that it hints that investors may have gotten a little overenthusiastic about the company's prospects. Sure, the long-term opportunity could be huge, but how much of that appeal has already been baked into the share price? A price-to-earnings ratio of roughly 20 would require earnings of around $2 per share, which seems like an unlikely outcome over the near term given the large need for capital investments (to build and launch additional satellites). AST SpaceMobile is expensive So there's no question that AST SpaceMobile, assuming it executes well, has a very attractive story behind it. That's not the problem with the stock. The problem is that Wall Street often gets a story in its teeth and runs too far and too fast with it. That seems like it might be happening with AST SpaceMobile right now. If you buy it, remember that it is still just a start-up company. You may have to stick around for a long time to benefit given the swift price advance already experienced by the shares. Worse, you may have to sit through a deep drawdown if there are any setbacks, or if the business doesn't develop quickly enough for Wall Street. In other words, AST SpaceMobile is probably only appropriate for more aggressive investors with a very long-term investment horizon. Should you invest $1,000 in AST SpaceMobile right now? Before you buy stock in AST SpaceMobile, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AST SpaceMobile wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor 's total average return is1,048% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
National Post
2 hours ago
- National Post
Colby Cosh: How Donald Trump nationalized U.S. Steel
Last week, Nippon Steel Corp. of Japan formally completed a takeover of U.S. Steel (USS), the venerable but diminished American industrial giant created by J.P. Morgan in 1901. The Japanese company originally placed its bid for USS in late 2023, but it ran into immediate trouble with the Biden administration. U.S. Steel, once widely regarded as an overmighty pollution-spewing relic of Gilded Age cartelization, had magically evolved to become a vulnerable 'national champion' of morally superior things-making industries; and the company still has a powerful unionized workforce in U.S. rust-belt states that are electorally pivotal. Pennsylvania-born President Joe Biden wasn't going to let a corporate brand virtually synonymous with the city of Pittsburgh be raffled off without a tussle. Article content Article content Government foreign-investment approvals necessarily have this sort of personal-rule character wherever they happen, which is pretty much everywhere. If you want to sell a bundle of industrial assets in Country X to folks from Country Y, you had better have approval from the top political boss of X, whether that approval be tacit or explicit. Article content Article content Article content Still, Biden did go through the motions of being head of a government of laws rather than men. He had a U.S. Treasury Department panel, the Committee on Foreign Investment in the United States (CFIUS), whack together an indecisive but fact-based report on the potential costs and benefits of the proposed takeover. Only at that point, with mere days remaining in his term of office, did Biden (or whoever was wielding his executive autopen) fully and officially block the Nippon Steel deal. Biden's successor had already been re-elected, and nobody could imagine that Donald Trump would be any less of an unruly economic nationalist — but the thing that is nearest and dearest to Trump's heart is deal-making, and Nippon Steel found a way to get the takeover done. The Japanese company had already promised to preserve U.S. Steel's Pittsburgh national head office and to honour existing collective-bargaining agreements with the unions. Trump extracted further concessions on investments and hiring, along with a means of enforcing them, namely a 'golden share' controlled by the U.S. government. Article content A 'golden share' is a special kind of equity that gives its holder veto power over specified corporate decisions. It is often used in privatizations to give governments some vestige of control over corporate entities originally created by the state (or, in Canada, the Crown) for public purposes. In this unusual case, the U.S. government is magically gaining a golden share in exchange for permitting the sale of one private company to another. The government will be given the right to choose some U.S. Steel board directors, to forbid any name change, and to veto factory closures, offshoring, acquisitions and other moves. Article content As the Cato Institute immediately pointed out, this is a de facto nationalization of U.S. Steel — the sort of thing that would have had Cold War conservatives climbing the walls and hooting about socialism. But at least socialism professes to be social! Yesterday a lefty energy reporter named Robinson Meyer was nosing around in the revised corporate charter for the newly-acquired U.S. Steel, and he discovered a remarkable detail that the Cato folks had missed: the decision powers of the golden share have been legally assigned to Donald Trump in person and by name for the duration of his presidency. Only after Trump has left the White House do those golden-share powers revert to actual U.S. government departments (Treasury and Commerce).
National Post
13 hours ago
- National Post
SBC Medical added to membership of Russell 3000® Index
Article content IRVINE, Calif. — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Article content Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Article content Article content Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments: 'The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.' Article content For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. Article content About SBC Medical Article content SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. Article content For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. Article content FTSE Russell is wholly owned by London Stock Exchange Group. Article content Forward-Looking Statements Article content This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at Article content Article content Article content
